

Applicants : Stanley M. Crain and Kei-Fei Shen
Appn. No. : Not Yet Assigned (Cont. of 09/585,517)
Filed : Herewith
Page 2

A1 Ref
U.S. Patent No. 5,512,578 and reissued as U.S. Reissue Patent No. 36,547, which is a continuation-in-part of Application No. 08/097,460, filed July 27, 1993, now U.S. Patent No. 5,472,943, which is a continuation-in-part of Application No. 07/947,690, filed September 19, 1992, now abandoned, the contents of which are hereby incorporated by reference in their entirety.--

101 201 301 401 501 601 701 801 901
In the Claims:

Please cancel Claims 1-29 without prejudice to applicants' right to pursue prosecution of these claims in a later-filed continuation application.

A2 202 302 402 502 602 702 802 902
Please add new Claims 30-48 as follows:

A2
30. (new) A method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist and simultaneously attenuating tolerance associated with the administration of said bimodally-acting opioid agonist, comprising administering to a subject a composition comprising an analgesic or sub-analgesic amount of said bimodally-acting opioid agonist and an amount of an excitatory opioid receptor antagonist effective to enhance the analgesic potency of said bimodally-acting opioid agonist and attenuate tolerance associated with said bimodally-acting opioid agonist.

2
31. (new) The method of Claim 30, wherein the excitatory opioid receptor antagonist is selected from the group consisting of naltrexone, naloxone, etorphine, diprenorphine, dihydroetorphine, and similarly acting opioid alkaloids and opioid peptides.